Global H1N1 Vaccines Industry

NEW YORK, June 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global H1N1 Vaccines industry

http://www.reportlinker.com/p0197196/Global-H1N1-Vaccines-industry.html

This report analyzes the Global market for H1N1 Vaccines in US$ Million. Annual estimates and forecasts are provided for the period 2009 through 2015. The report profiles 21 companies including Baxter International, Inc., CPL Biologicals Pvt. Ltd., CSL Limited, GlaxoSmithKline Plc, MedImmune, LLC, Novartis AG, Sanofi Pasteur, SA, Simcere Pharmaceutical Group, Sinovac Biotech Ltd., Solvay SA, and Zydus Cadila. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

H1N1 VACCINES MCP-6274

A GLOBAL MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW II-1

Influenza A (H1N1) 2009: The Global Pandemic II-1

Swine Flu Badly Hits Economy II-1

H1N1 Concerns Spell Boom for Hand Sanitizers Market II-2

H1N1 Vaccines: A Weapon to Combat the New Flu Virus II-2

US DHHS Allocates US$1 Billion for Developing H1N1 Vaccine II-2

H1N1 Vaccines Hit the Market in August 2009 II-2

H1N1 Influenza Vaccines and Manufacturers II-3

Specific Anti-Viral Drugs Witness Increasing Orders II-4

Pharma Majors Try Combination Therapies Against H1N1 II-4

Need for Effective Anti-Virals Against H1N1 Virus Grows II-4

H1N1 Pandemic Now "Moderately" Severe II-4

Demand for H1N1 Vaccines to Gradually Fade II-5

Current and Future Analysis II-5

2. A REVIEW OF SELECT H1N1 VACCINES II-6

Celtura® (Novartis) II-6

Focetria® (Novartis) II-6

Fluvirin® (Novartis) II-6

Panenza® (Sanofi Pasteur) II-6

Humenza (Sanofi Pasteur) II-6

Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur) II-6

Major H1N1 Vaccines Available in Different Geographic Regions II-7

H1N1 Influenza Vaccines Available in Europe, by Select Region II-7

FDA-Approved H1N1 Vaccines in the US, By Manufacturer II-8

H1N1 Vaccines Approved For Use in Canada II-8

H1N1 Flu Vaccines Available in Asia Pacific, by Select

Country/Region II-8

H1N1 Flu Vaccines Available in Other Selected Global

Country/Region II-8

3. REGIONAL MARKET PERSPECTIVE II-9

India II-9

Zydus Becomes the First Company to Register H1N1 Clinical

Trials in India II-9

India May Expect H1N1 Vaccine by April 2010 II-9

Generic Anti-Virals Abound for H1N1 Treatment II-9

Table 1: Major Oseltamivir Generics in India, Breakdown by

Cost (includes corresponding Graph/Chart) II-10

China II-10

China Boosts (H1N1) Influenza A Vaccines Volume II-10

Over 3.7 Million Chinese Immunized Against H1N1 II-10

Singapore II-11

Singapore Health Ministry Bolsters National Stockpile of

H1N1 Vaccines II-11

Australia II-11

Australian Government Awards Supply Contract to CSL Ltd II-11

Europe II-11

Select European Countries to Return Unused Vaccines II-11

4. WORLDWIDE H1N1 PANDEMIC SITUATION II-12

North America II-12

Mexico II-12

The United States II-12

Canada II-12

Japan II-12

Europe II-13

Asia-Pacific II-13

Hong Kong II-13

South Korea II-13

Taiwan II-13

Malaysia II-13

Philippines II-14

Singapore II-14

India II-14

Australia II-14

New Zealand II-14

H1N1 Cases Worldwide - A Statistical Review by Select

Geographic Region II-15

Table 2: H1N1 Pandemic Situation in Select Countries

Worldwide: Confirmed Cases and Deaths Due to the Infection

(includes corresponding Graph/Chart) II-15

Table 3: Pandemic (H1N1) Situation by Select Global Country:

Suspected Cases and Confirmed Deaths Due to the Infection

(includes corresponding Graph/Chart) II-16

Table 4: Select Global Countries with Suspected H1N1 Cases,

But no Deaths (includes corresponding Graph/Chart) II-17

5. H1N1 INFLUENZA - A RESPIRATORY VIRUS II-18

What are Respiratory Viruses? II-18

Influenza Virus: A Quick Primer II-18

Symptoms and Characteristics II-18

Types of Influenza II-18

Influenza A Virus II-18

Influenza A (H1N1) Virus II-18

Different Names, in Different Countries II-19

Symptoms and Risk Factors II-19

Seasonal Influenza Vis-à-Vis H1N1 Flu II-20

How H1N1 Is Diagnosed? II-20

Prevention, and Vaccination Against H1N1 II-20

Prevention II-20

Vaccination II-20

How H1N1 Vaccine is Prepared? II-21

Egg-Based Production Process II-21

Cell Culture-Based Technology II-22

Side Effects of H1N1 Vaccine II-22

Primary Targets for Vaccination II-22

Adverse Group for Vaccination II-23

Treatment for Swine-Flu Infected Individuals II-23

Anti-Virals for Pandemic (H1N1) 2009 Infection II-23

Recommended Dosage of Anti-Virals II-24

Peramivir - An Investigational Antiviral for H1N1 II-24

6. REGULATORY APPROVALS II-25

CSL Biotherapies Receives TGA Approval for Panvax® H1N1 II-25

WHO Prequalifies Arepanrix™ H1N1 Vaccine of GlaxoSmithKline II-25

CSL Obtains Approval for Extended Use of 2009 HINI Influenza

vaccine in Infants II-25

Novartis Receives Approval for Celtura® II-25

Baxter Obtains Approval for Vero Cell-Based CELVAPAN H1N1

Vaccine in Europe II-26

CHMP Recommends Approval of Novartis' Focetria® in Europe II-26

Sanofi Pasteur Obtains License from the US FDA for Influenza

A (H1N1) 2009 Monovalent Vaccine II-26

Sanofi Pasteur Receives Approval for New Vaccine Production

Facility II-26

US FDA Approves Supplemental BLA of GSK, for Unadjuvanted

Influenza A (H1N1) Pandemic Vaccine II-27

Health Canada Approves H1N1 Virus Vaccine II-27

Sanofi Pasteur Gains Approval of Afssaps for A (H1N1) 2009

Vaccine in France II-27

Novartis Obtains Prequalification Status from the WHO for

Supply of Influenza A (H1N1) 2009 Vaccines in Developing

World II-27

Novartis Obtains Swissmedic Approval for Celtura® II-28

CSL Biotherapies Receives US FDA Licensure for its

Thimerosal-free Pandemic Influenza A (H1N1) 2009 Monovalent

Vaccine II-28

MedImmune Receives US FDA Approval for Nasal Spray H1N1 Vaccine II-28

Sinovac Obtains Revised Approval for PANFLU.1 (H1N1) from

State Food and Drug Administration II-29

Sinovac Gains Certificate of Approval for Supply of PANFLU.1

in Mexico II-29

Jiangsu Yanshen Gains Manufacturing License from SFDA, for

H1N1 Flu Vaccine II-29

7. RECENT INDUSTRY ACTIVITY II-30

Sinovac Biotech Clinches Fifth Consecutive Supply Order from

MIIT for Panflu.1 H1N1 Vaccine II-30

Zydus Cadila Completes Phase I Clinical Trial With its H1N1

Vaccine II-30

Cadila Pharmaceuticals and Novavax Launches CPL Biologicals

Pvt. Ltd. II-30

Novartis Delivers 7.5 Million Doses of Influenza A (H1N1)

Vaccine to HHS II-31

Novartis Opens New Production Facility for Cell Culture-Based

Influenza Vaccines Production in the United States II-31

Novartis to Takeover Majority Interest in Chinese H1N1

Vaccine Maker II-31

PhageVax Launches DNA Vaccine Platform II-31

NIH to Initiate 2009 H1N1 Influenza Vaccine Trial in Persons

with Asthma II-32

Inovio Teams Up with Canadian Health Agency Pennsylvanian

University on Swine Flu Vaccine II-32

Simcere to Acquire Majority Interest in ChinaVax II-32

Sanofi Pasteur Clinches Additional Order from HHS Department

of the US II-32

Sanofi Pasteur Bags Order from French Health Ministry, for

Influenza A (H1N1) Vaccine II-33

Sanofi Pasteur Inks Deal with Butantan Institute for Supply

of Influenza A (H1N1) Virus Vaccine II-33

McKesson Extends Partnership Deal with CDC II-33

BD Receives Order from the Department of HHS II-33

GSK Receives Order from the Department of HHS II-33

MedImmune Recalls 4.7 Million Courses of Nasal H1N1 Flu Vaccine II-34

Novavax and Xcellerex Enter into a Partnership II-34

8. FOCUS ON SELECT GLOBAL PLAYERS II-35

Baxter International, Inc. (US) II-35

CPL Biologicals Pvt. Ltd (India) II-35

CSL Limited (Australia) II-35

GlaxoSmithKline Plc (UK) II-36

MedImmune, LLC. (USA) II-37

Novartis AG (Switzerland) II-37

Sanofi Pasteur, SA (France) II-37

Simcere Pharmaceutical Group (China) II-38

Sinovac Biotech Ltd (China) II-39

Solvay SA (Belgium) II-39

Zydus Cadila (India) II-39

9. GLOBAL MARKET PERSPECTIVE II-40

Table 5: World Recent Past, Current & Future Analysis for

H1N1 Vaccines by Geographic Region - US, Europe,

Asia-Pacific, and Rest of World Markets Independently

Analyzed by Annual Sales Figures in US$ Million for the Years

2009 through 2015 (includes corresponding Graph/Chart) II-40

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 22 (including Divisions/Subsidiaries - 26)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 7

Canada 1

Japan 1

Europe 6

France 1

The United Kingdom 2

Rest of Europe 3

Asia-Pacific (Excluding Japan) 11

------------------------------------------

To order this report:

Drug and Medication Industry: Global H1N1 Vaccines industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo